Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer and Regeneron announce eye disease collaboration

Bayer and Regeneron announce eye disease collaboration

30th March 2016

Bayer and Regeneron Pharmaceuticals are allying to assess the benefits of a new combination therapy for serious eye diseases.

The collaboration will involve the development of a new combination of the angiopoietin2 antibody nesvacumab and the vascular endothelial growth factor trap aflibercept, which can influence the pathological development of new blood vessels and the permeability of blood vessel walls.

Two phase II clinical studies are currently ongoing to evaluate the combination therapy as a co-formulated single intravitreal injection, known as REGN910-3, in patients with wet age-related macular degeneration or diabetic macular oedema.

Regeneron will receive a $50 million (34.76 million pounds) upfront payment, with the two companies sharing global development costs. Bayer will have exclusive commercialisation rights to the product and will share potential profits equally, other than in the US, where Regeneron retains exclusive rights.

Dr Joerg Moeller, member of the executive committee of Bayer's pharmaceuticals division and head of development, said: "Inhibiting the angiopoietin2 pathway is a promising new approach for a combination therapy, and we are looking forward to working on it together with Regeneron."ADNFCR-8000103-ID-801815534-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.